The limits of a drug therapy in severe forms of Parkinson disease have led to refining neurosurgery on the basal ganglia. Deep brain stimulation of the subthalamic nucleus has been recognized as one of the most promising techniques to decrease "off" motor symptoms and motor fluctuations, allowing a reduction of drug therapy and limiting side effects of the drugs. There is still open debate on the possible consequences of chronic subthalamic stimulation in other ways, apart from motor symptoms, of general cognitive performance. We examined and followed two patients with Parkinson disease for 9 mo. after surgery for deep stimulation, studying their cognitive performances. There is a general amelioration of cognitive performances, in particular as far as linguistic capabilities is concerned. We discuss the possible significance of these results, reminding strenuously that only two patients were involved, so the potential for generalization is seriously limited.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2466/pms.2002.95.2.477 | DOI Listing |
Dokl Biol Sci
January 2025
Research Center of Neurology, Moscow, Russia.
Characteristic patterns of UV-induced skin autofluorescence were determined for patients with Parkinson's disease (PD) and associated with dysmetabolic alterations, such as nonenzymatic protein glycation, an increase in extracellular matrix stiffness, impaired metabolism of tissue fluorophores, mitochondrial dysfunction, and accumulation of aberrant proteins. Key differences in skin autofluorescence spectra were for the first time observed in PD, making it possible to discriminate between PD patients and healthy persons or individuals without signs of chronic neurodegeneration. Namely, skin fluorescence related to the reflected signal upon excitation with UV light at 375 nm was lower in PD patients.
View Article and Find Full Text PDFNeurosurg Rev
January 2025
Department of Neurosurgery, Hospital Universitario Fundación Jiménez Díaz, Av. De los Reyes Católicos, 2, Madrid, 28040, Spain.
Matched-controlled long-term disease evaluation and neuropsychological outcomes derived from deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson´s disease (PD) are lacking, with inconsistent results regarding the cognitive impact of this procedure. Here we study the long-term effects associated to DBS comparing outcomes with a matched control group. A prospective observational study of 40 patients with PD with bilateral STN-DBS, with a mean follow-up of 9 (6-12) years was conducted.
View Article and Find Full Text PDFCell Biol Toxicol
January 2025
Department of Environmental Medicine, School of Medicine, Chongqing University, Chongqing, China.
Manganese (Mn) is a neurotoxin that has been etiologically linked to the development of neurodegenerative diseases in the case of overexposure. It is widely accepted that overexposure to Mn leads to manganism, which has clinical symptoms similar to Parkinson's disease (PD), and is referred to as parkinsonism. Astrocytes have been reported to scavenge and degrade extracellular α-synuclein (α-Syn) in the brain.
View Article and Find Full Text PDFJ Neural Transm (Vienna)
January 2025
Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
Parkinson's disease (PD) is a chronic neurodegenerative disease of the elderly. Patients suffer from progressive motor and non-motor symptoms. Further, PD patients often present geriatric features like multimorbidity and polypharmacotherapy.
View Article and Find Full Text PDFMov Disord Clin Pract
January 2025
Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Hôpital de la Salpêtrière, INSERM, CNRS, Paris, France.
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and nonmotor symptoms, with a significant genetic component. Early-onset Parkinson's disease (EOPD), manifesting before age 45, is often linked to mutations in genes such as PARK2, PINK1, and PARK7, the latter coding for the protein DJ-1.
Objective: We present the first reported cases of EOPD carrying a previously undescribed homozygous PARK7 mutation, p.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!